Neurogene (NASDAQ:NGNE) and Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison

Rapport Therapeutics (NASDAQ:RAPP) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Rapport Therapeutics and Neurogene”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$34.79 million	($13.84)	-0.74
Neurogene	$925,000.00	218.60	-$36.32 million	N/A	N/A

Rapport Therapeutics has higher earnings, but lower revenue than Neurogene.

Analyst Ratings

This is a summary of recent ratings and price targets for Rapport Therapeutics and Neurogene, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0	0	3	0	3.00
Neurogene	0	0	7	1	3.13

Rapport Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 241.13%. Neurogene has a consensus price target of $60.80, indicating a potential upside of 346.66%. Given Neurogene’s stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than Rapport Therapeutics.

Profitability

This table compares Rapport Therapeutics and Neurogene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Neurogene	N/A	-32.81%	-27.96%

Institutional & Insider Ownership

52.4% of Neurogene shares are owned by institutional investors. 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Neurogene beats Rapport Therapeutics on 7 of the 10 factors compared between the two stocks.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.